Cytochrome P450 Oxidoreductase Contribution On An Acenocoumarol Dosing Algorithm

August 2015 e131 Sant Pau, Barcelona, Spain; Universitat Autonoma de Barcelona, Barcelona, Spain; IDIAP Jordi Gol, Barcelona, Spain; and SAP Barcelones Nord i Maresme, Institut Catala de la Salut, Barcelona, Spain Background or Introduction: Generic Drugs Products (GDP) have been subject of discussion for many years, and still now there is some controversy about their quality, effectiveness and safety compared to Innovators drugs. This survey tried to find what is the general perception and opinion from physicians and medical students about generic drugs products. Material and Methods: A questionnaire of 12 items focused mainly in effectiveness, safety, quality and adverse event occurrence was sent to physicians of a third level health care hospital and to medicine students. Individual demographic information and clinical practice data (specialty, years of experience, pharmaceutical sale representative visits, etc.) was asked. Results: One hundred fifty-five subjects answered the survey (n = 157). Physicians from specialties that are less related with clinical practice (who do not prescribe daily) showed to be more agreed with the affirmation that Innovators and GDP products have the same quality, effectiveness and adverse event occurrence compare with physician’s that prescribe daily. Internal medicine specialist tends to be more agreed with equivalence in term of effectiveness and adverse events occurrence than surgical specialist. Years of experience, number of patients by day and number of pharmaceutical sales representative’s visits by month showed an inversely proportional relationship to be in agreement with equivalence in quality, effectiveness and safety. Difference between medicine students and physician were found in questions related to quality, effectiveness and safety, physicians tend to be more in disagreement with the equivalence in those aspects between GDP and Innovators ones. All commented results were statistically significant (P values u003c 0.05). Conclusions: We found that physicians have some concerns about equivalence between GDP and Innovators ones regarding the quality, efficacy and safety of generic drugs, this concerns increase with years’ experience, number of patients visited and number of sales representatives visits, the fact of prescribing daily and to be surgical specialist. Students tend to be more agreed with equivalence between GDP and Innovators drugs. Nevertheless the response rate is a limitation of this study.